Islet amyloid is associated with decreased ?-cell mass and decreased ?-cell function in type 2 diabetes. The unique peptide component of these amyloid deposits is islet amyloid polypeptide (IAPP). We hypothesize that in the presence of ?-cell dysfunction, increased ?-cell secretory demand results in the deposition of IAPP as islet amyloid. Under these conditions, the accumulation of this amyloidogenic peptide occurs by increased production and is associated with activation of stress-activated cellular signaling pathways leading to ?-cell apoptosis. Three major specific aims focusing on the pathogenesis and impact of islet amyloid will address this hypothesis. 1. To determine the site of islet amyloid formation and how this determines its cytotoxicity; 2. To determine the role of oxidative stress and inflammatory stress in islet amyloid formation in vitro; and 3. To determine whether oxidative stress and proinflammatory cytokines are determinants of amyloid deposition in vivo. We will measure islet, ?-cell and amyloid areas, rates of ?-cell replication and apoptosis, islet cell viability, islet content of insulin and IAPP, ?-cell secretory function, markers of oxidative stress, proinflammatory cytokines, and activation of the NF-?B and JNK pathways. Measurements will be made in two different models of islet amyloidogenesis (in vitro islet culture and in vivo islet transplantation), both based on our human IAPP transgenic mouse model of islet amyloid. These studies will provide important information about the pathogenesis of islet amyloid and should thus allow the future development of approaches to prevent ?-cell loss and the development and progression of type 2 diabetes.

Public Health Relevance

Protein deposits called amyloid accumulate in the pancreas and destroy insulin producing cells, thus contributing to the development of type 2 diabetes. This proposal will examine mechanisms by which these deposits form in order to try and prevent their formation and the loss of insulin producing cells. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK075998-01A2
Application #
7464566
Study Section
Cellular Aspects of Diabetes and Obesity Study Section (CADO)
Program Officer
Appel, Michael C
Project Start
2008-08-01
Project End
2012-07-31
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
1
Fiscal Year
2008
Total Cost
$288,363
Indirect Cost
Name
Seattle Institute for Biomedical/Clinical Research
Department
Type
DUNS #
928470061
City
Seattle
State
WA
Country
United States
Zip Code
98108
Rhodes, Christopher J; White, Morris F; Leahy, John L et al. (2013) Direct autocrine action of insulin on ?-cells: does it make physiological sense? Diabetes 62:2157-63
Aston-Mourney, Kathryn; Zraika, Sakeneh; Udayasankar, Jayalakshmi et al. (2013) Matrix metalloproteinase-9 reduces islet amyloid formation by degrading islet amyloid polypeptide. J Biol Chem 288:3553-9
Kahn, Steven E (2013) Quantifying ?-cells in health and disease: the past, the present, and the need. Diabetes Care 36:4-5
Subramanian, S L; Hull, R L; Zraika, S et al. (2012) cJUN N-terminal kinase (JNK) activation mediates islet amyloid-induced beta cell apoptosis in cultured human islet amyloid polypeptide transgenic mouse islets. Diabetologia 55:166-74
Aston-Mourney, K; Hull, R L; Zraika, S et al. (2011) Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets. Diabetologia 54:1756-65
Jurgens, Catherine A; Toukatly, Mirna N; Fligner, Corinne L et al. (2011) ?-cell loss and ?-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol 178:2632-40
Zraika, S; Hull, R L; Verchere, C B et al. (2010) Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence? Diabetologia 53:1046-56
Masters, Seth L; Dunne, Aisling; Subramanian, Shoba L et al. (2010) Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1? in type 2 diabetes. Nat Immunol 11:897-904
Hull, R L; Zraika, S; Udayasankar, J et al. (2009) Amyloid formation in human IAPP transgenic mouse islets and pancreas, and human pancreas, is not associated with endoplasmic reticulum stress. Diabetologia 52:1102-11
Kahn, S E; Zraika, S; Utzschneider, K M et al. (2009) The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality. Diabetologia 52:1003-12

Showing the most recent 10 out of 11 publications